US Patent Issued to Orionis Biosciences, Orionis Biosciences on Nov. 18 for "Targeted engineered interferon and uses thereof" (Belgian, American Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,473,338, issued on Nov. 18, was assigned to Orionis Biosciences Inc. (Waltham, Mass.) and Orionis Biosciences BV (Ghent, Belgium).

"Targeted engineered interferon and uses thereof" was invented by Nikolai Kley (Waltham, Mass.), Lennart Zabeau (Ghent, Belgium) and Jan Tavernier (Ghent, Belgium).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents."

The patent was filed on Dec. 24, 2020, under Application No. 17/133,782.

*For further information, including images, charts and tables, please visit: http://patft.u...